Lung involvement prevalence in patients with early rheumatoid arthritis without known pulmonary disease: a multicentric cross sectional study
Tóm tắt
Clinically evident interstitial lung disease (ILD) affects between 10 and 42% of the patients with rheumatoid arthritis (RA). Airway involvement seems to be even more common. Most of the available evidence comes from studies performed in established RA patients. The aim of our study was to know the prevalence of non-diagnosed lung disease (airway and interstitial involvement) in patients with early RA and look for associated factors. We designed an observational, multicenter, cross-sectional study, and included patients with RA of less than two years since diagnosis. We performed a structured questionnaire, HRCT and lung functional tests looking for lung disease, together with joint disease evaluation. We analyzed which variables were associated with the presence of lung disease on HRCT. We included 83 patients, 83% females. The median (IQR) of time since RA diagnosis was 3 (1–6) months. In the HRCT, 57 patients had airway compromisea (72%), and 6 had interstitial abnormalities (7.5%). The most common altertion found in lung functional tests was a reduced DLCO (14%). The presence of at least one abnormality in the physical exam was associated with lung involvement on HRCT [13 (21.6%) vs 0 (0%); p = 0.026]. Also, patients with lung involvement presented significantly lower values of FVC% and DLCO%, and higher values of RV/TLC. No variable related to joint involvement was found associated with alterations in HRCT. Our study shows that a large proportion of early RA patients has abnormal findings in HRCT. Further studies are required to confirm these findings.
Tài liệu tham khảo
Rooney BK, Silman AJ. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol. 1999;11(2):91–7.
Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995–2007 versus 1985–1994: a population-based study. J Rheumatol. 2011;38(6):983–9.
Antin-Ozerkis D, Evans J, Rubinowitz A, et al. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med. 2010;31(3):451–78.
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.
Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46(2):350–7.
Zou Y-Q, Li Y-S, Ding X-N, et al. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int. 2012;32(3):669–73.
Richman NC, Yazdany J, Graf J, et al. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore). 2013;92(2):92–7.
Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis—interstitial lung disease—associated mortality. Am J Respir Crit Care Med. 2011;183:372–8.
Bongartz T, Nannini C, Medina-velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population based study. Arthritis Rheum. 2010;62(6):1583–91.
Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–8.
Demoruelle MK, Weisman MH, Simonian PL, et al. Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64(6):1756–61.
Yin Y, Liang D, Zhao L, et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS ONE. 2014;9(4):1–6.
Rocha-Muñoz AD, Ponce-Guarneros M, Gamez-Nava JI, et al. Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis. J Immunol Res. 2015;2015:1–10.
Young A. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology (Oxford). 2014;53(9):1676–82.
Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–66.
Dawson JK, Fewins HE, Desmond J, et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(6):517–21.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81. https://doi.org/10.1002/art.27584.
Dai Y, Wang W, Yu Y, et al. Rheumatoid arthritis–associated interstitial lung disease an overview of epidemiology, pathogenesis and management. Clin Rheumatol. 2021. https://doi.org/10.1007/s10067-020-05320-z.
Bendstrup E, Møller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med. 2019;2038:1–21. https://doi.org/10.3390/jcm8122038.
Wilsher M, Voight L, Milne D, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respiratory Med. 2012;106(10):1441–6.
Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–6. https://doi.org/10.1002/art.20018.
Rocha-Muñoz AD, Ponce-Guarneros M, Gamez-Nava JI, et al. Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis. J Immunol Res. 2015. https://doi.org/10.1155/2015/151626.
Zhu J, Zhou Y, Chen X, et al. A meta analysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol. 2014;41:1282–9.
Chung MH, Lee HL, Kwon SS, et al. Air obstruction in rheumatoid arthritis: CT manifestations correlated with pulmonar function testing. Yonsei Medi J. 2004;45(3):443–52.
Salaffi F, Carotti M, Di Carlo M, et al. High-resolution computed tomography of the lung in patients with rheumatoid arthritis. Medicine. 2019;98:38.
Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology. 2014;53:1676–82.
Kawano-Dourado L, Doyle TJ, Bonfiglioli K, et al. Baseline characteristics and progression of a spectrum of interstitial lung abnormalities and disease in rheumatoid arthritis. Chest. 2020;158(4):1546–54. https://doi.org/10.1016/j.chest.2020.04.061.
Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-a autoantibody system. Autoimmunity Rev. 2009;8(7):632–7. https://doi.org/10.1016/j.autrev.2009.02.010.